Homozygous A polymorphism of the complement C1qA 276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Jin, Xuan ^a   Ding, Huirong ^b   Ding, Ning ^c   Fu, Zhiying ^c   Song, Yuqin ^c   Zhu, Jun ^c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Department of Biochemistry and Molecular BiologyCancer Hospital of Peking University   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

C1qA; Complement; DLBCL; Polymorphism; Rituximab

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1QA; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; DNA POLYMORPHISM; DRUG EFFICACY; FEMALE; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPLEMENT C1Q; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HOMOZYGOTE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84864911803     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-51     Document Type: Article

References (25)

1. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL, Figgitt DP, Drugs 2003 63 803 843 10.2165/00003495-200363080-00005 12662126
2. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. N Engl J Med 2002 346 235 242 10.1056/NEJMoa011795 11807147
3. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, et al. J Clin Oncol 2005 23 4117 4126 10.1200/JCO.2005.09.131 15867204
4. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, et al. J Clin Oncol 2006 24 3121 3127 10.1200/JCO.2005.05.1003 16754935
5. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, et al. Lancet Oncol 2006 7 379 391 10.1016/S1470-2045(06)70664-7 16648042
6. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, J Hematol Oncol 2010 3 5 10.1186/1756-8722-3-5 20132536
7. The four types of Tregs in malignant lymphomas. Wang J, Ke XY, J Hematol Oncol 2011 4 50 10.1186/1756-8722-4-50 22151904
8. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. Wu ZL, Song YQ, Shi YF, Zhu J, J Hematol Oncol 2011 4 31 10.1186/1756-8722-4-31 21806788
9. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR, J Hematol Oncol 2011 4 16 10.1186/1756-8722-4- 16 21504625
10. Digitoxin and its analogs as novel cancer therapeutics. Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C, Experimental Hematology & Oncology 2012 1 4 10.1186/2162-3619-1-4 23042582
11. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, et al. Blood 2003 101 4279 4284 10.1182/blood-2002-11-3442 12576316
12. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, et al. Blood 2002 99 67 74 10.1182/blood.V99.1.67 11756154
13. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, et al. Blood 2002 99 1038 1043 10.1182/blood.V99.3.1038 11807010
14. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Shan D, Ledbetter JA, Press OW, Cancer Immunol Immunother 2000 48 673 683 10.1007/s002620050016 10752475
15. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, et al. Blood 2000 95 3900 3908 10845926
16. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Harjunpaa A, Junnikkala S, Meri S, Scand J Immunol 2000 51 634 641 10.1046/j.1365-3083.2000.00745.x 10849376
17. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, et al. J Immunol 2000 164 4178 4184 10754313
18. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Cragg MS, Glennie MJ, Blood 2004 103 2738 2743 10.1182/blood-2003-06- 2031 14551143
19. Complement activation determines the therapeutic activity of rituximab in vivo. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, et al. J Immunol 2003 171 1581 1587 12874252
20. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, et al. Clin Cancer Res 2008 14 6697 6703 10.1158/1078-0432.CCR-08-0745 18927313
21. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, et al. J Clin Oncol 1999 17 1244 10561185
22. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, et al. Hum Mol Genet 2003 12 205 216 10.1093/hmg/ddg055 12554675
23. The relationship between third-codon position nucleotide content, codon bias, mRNA secondary structure and gene expression in the drosophilid alcohol dehydrogenase genes Adh and Adhr. Carlini DB, Chen Y, Stephan W, Genetics 2001 159 623 633 11606539
24. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. Pike SE, Yao L, Jones KD, Cherney B, Appella E, et al. J Exp Med 1998 188 2349 2356 10.1084/jem.188.12.2349 9858521
25. Localisation of the C1q binding site within C1q receptor/calreticulin. Stuart GR, Lynch NJ, Lu J, Geick A, Moffatt BE, et al. FEBS Lett 1996 397 245 249 10.1016/S0014-5793(96)01156-8 8955356